ACE Inhibitor and ARB Contraindications in CKD

Absolute Contraindications

Bilateral renal artery stenosis is the sole true contraindication to ACE inhibitors and ARBs, as they can precipitate acute kidney injury by preventing compensatory efferent arteriolar vasoconstriction in this setting, according to the European Heart Journal 1, 2

The combination of ACE inhibitors with ARBs must be avoided in all CKD patients, as it increases risks of hyperkalemia and acute kidney injury without providing additional cardiovascular or renal benefits, as stated by the American Diabetes Association, based on evidence from Diabetes Care 3, 4

ACE inhibitors and ARBs remain beneficial even in advanced CKD but require closer monitoring, and consider nephrology referral when eGFR falls below 30 mL/min/1.73 m², as recommended by the American Diabetes Association, based on evidence from Diabetes Care 3, 4
Do not discontinue ACE inhibitors or ARBs based solely on eGFR decline, as an initial creatinine rise of up to 30% is acceptable and typically returns to baseline, according to the European Heart Journal 1, 2

Serum creatinine should be checked within 1-2 weeks of initiation and after dose changes, and accept up to 30% increase, as recommended by the European Heart Journal 1, 2
Serum potassium should be monitored within 1 month of initiation, after dose adjustments, and periodically during therapy, as recommended by the American Diabetes Association, based on evidence from Praxis Medical Insights: Practical Summaries of Clinical Guidelines 5

Choose either ACE inhibitor or ARB, never both, and start at standard or reduced doses depending on eGFR and volume status, as recommended by the American Diabetes Association, based on evidence from Diabetes Care 3, 4
Accept creatinine increases up to 30% and continue therapy, as recommended by the European Heart Journal 1, 2
Optimize single-agent dosing rather than adding a second RAS blocker, as recommended by the American Diabetes Association, based on evidence from Praxis Medical Insights: Practical Summaries of Clinical Guidelines 6